Finance entity
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention 340B Drug Pricing Program, the most common co-covered peer. The 6 average consequence score is above the beat benchmark of 5.4 in the same window.
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
markets is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention 340B Drug Pricing Program, the most common co-covered peer. The 6 average consequence score is above the beat benchmark of 5.4 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. Section 232 of the Trade Expansion Act appears in 1 tracked Finance story from August 7, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 43 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Section 232 of the Trade Expansion Act. Shared-story counts are live from our verified record — not editorial picks.
The 100% then 200% tariffs on generic drugs represent a systemic risk to the U.S. generic pharmaceutical market. With margins already compressed and price pass-through blocked, investors should brace for product exits, consolidation, and potential supply chain disruptions that could raise overall healthcare costs.
Section 232 of the Trade Expansion Act is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
